Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | PGR | P06401 | 1/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.63 |
| ▸ | CBR1 | P16152 | 1/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.63 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Soneclosan SCHEMBL29359126 | 0.86 | TTR (0.66) | TTRMAPTHPGDNR1I2LMNA | |
| Soneclosan SCHEMBL465591 | 0.86 | TTR (0.66) | TTRMAPTHPGDNR1I2LMNA | |
| SCHEMBL10540653 | 0.85 | TTR (0.83) | TTRMAPTHPGDNR1I2LMNA | |
| SCHEMBL14861327 | 0.84 | TTR (0.50) | TTRMAPTHPGDNR1I2LMNA | |
| SCHEMBL10940178 | 0.82 | CYP1A2 (0.62) | TTRMAPTHPGDNR1I2LMNA | |
| SCHEMBL29352050 | 0.82 | CYP1A2 (0.62) | TTRMAPTHPGDNR1I2LMNA | |
| SCHEMBL11663615 | 0.80 | CA1 (0.43) | TTRMAPTHPGDNR1I2LMNA | |
| SCHEMBL13778174 | 0.79 | TTR (0.58) | TTRMAPTHPGDNR1I2LMNA | |
| SCHEMBL7182380 | 0.79 | TTR (0.58) | TTRMAPTHPGDNR1I2LMNA | |
| SCHEMBL7176805 | 0.79 | TTR (0.58) | TTRMAPTHPGDNR1I2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585751-A4 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | CELMED ONCOLOGY USA INC (CA) | 2008-08-13 | — | — | EP | claimed |
| JP-2006514009-A | — | — | 2006-04-27 | — | — | JP | claimed |
| US-20060063743-A1 | Peptide deformylase activated prodrugs | BALLATORE CARLO | 2006-03-23 | — | — | US | claimed |
| EP-1585751-A2 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | Celmed Oncology (USA), Inc. (CA) | 2005-10-19 | — | — | EP | claimed |
| US-20040236096-A1 | Peptide deformylase activated prodrugs | NEWBIOTICS, INC. | 2004-11-25 | — | — | US | claimed |
| WO-2004043400-A2 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | CELMED ONCOLOGY (USA), INC. (CA) | 2004-05-27 | — | — | WO | claimed |
| EP-1263762-A4 | ANTI-INFECTIVE ECTATM | NEWBIOTICS INC (US) | 2003-04-02 | — | — | EP | claimed |
| EP-1263762-A1 | ANTI-INFECTIVE ECTATM | Newbiotics Inc. (US) | 2002-12-11 | — | — | EP | claimed |
| WO-2001064687-A1 | ANTI-INFECTIVE ECTA?TM¿ | NEWBIOTICS, INC. (US) | 2001-09-07 | — | — | WO | claimed |
| EP-1585751-A4 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | CELMED ONCOLOGY USA INC (CA) | 2008-08-13 | — | — | EP | disclosed |
| US-7163923-B2 | Bactericides, fungicides, viricides | CELMED ONCOLOGY (USA), INC. (CA) | 2007-01-16 | — | — | US | disclosed |
| EP-1499318-A4 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | CELMED ONCOLOGY USA INC (CA) | 2006-07-19 | — | — | EP | disclosed |
| US-20060063743-A1 | Peptide deformylase activated prodrugs | BALLATORE CARLO | 2006-03-23 | — | — | US | disclosed |
| US-7001922-B2 | Peptide deformylase activated prodrugs | CELMED ONCOLOGY (USA), INC. (CA) | 2006-02-21 | — | — | US | disclosed |
| US-20030130179-A1 | Methods for identifying therapeutic targets for treating infectious disease | NEWBIOTICS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030091587-A1 | Peptide deformylase activated prodrugs | CELMED ONCOLOGY (USA), INC. (CA) | 2003-05-15 | — | — | US | disclosed |
| EP-1263762-A4 | ANTI-INFECTIVE ECTATM | NEWBIOTICS INC (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1263762-A1 | ANTI-INFECTIVE ECTATM | Newbiotics Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002007780-A2 | METHODS FOR IDENTIFYING THERAPEUTIC TARGETS | NEWBIOTICS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001064687-A1 | ANTI-INFECTIVE ECTA?TM¿ | NEWBIOTICS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063743-A1 | Peptide deformylase activated prodrugs | DNPEP, DPEP1, PEPD | TTR 3927/4885MAPT 4149/4885HPGD 732/4885 |
| US-20040236096-A1 | Peptide deformylase activated prodrugs | DNPEP, DPEP1, PEPD | TTR 4046/4885MAPT 4273/4885HPGD 850/4885 |
| US-20030130179-A1 | Methods for identifying therapeutic targets for treating infectious disease | GAA, GBA3, RNASE1 | TTR 3471/4885MAPT 3214/4885HPGD 851/4885 |
| US-20030091587-A1 | Peptide deformylase activated prodrugs | DNPEP, PREP, DPEP1 | TTR 3918/4885MAPT 4740/4885HPGD 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.